


Inside the Palais Ferstel



DRAFT PROGRAMME

The 3rd European Association of Addiction Therapy Conference 2007

10-12 September 2007
Palais Ferstel, Vienna, Austria

Chairs
Professor Gabriele Fischer
Dr Alfred Uhl

Programme and registration
available online at www.eaat.org

DRAFT PROGRAMME

European Association of Addiction Therapy Conference 2007

Day 1 – Monday 10th September 2007

- 08.00** Registration & Coffee
All
- 08.30** Introduction to Conference
G. Fischer (AT) & A. Uhl (AT)
- 08.45** Opening
Prof. Dr. Wolfgang Schütz, Rector of the Medical University of Vienna University (MUW)
Dr. Gilberto Gerra, Chief Global Challenges Section Human Security Branch, Division for Operations United Nations Office on Drugs and Crime (UNODC)
Dr. Johannes Hahn, Federal Minister of Science & Research (BMWF)

Session 1 – Cocaine: Epidemiology & New Treatment Access to Cocaine Addiction

Chairs: *J.K. Zubieta (US) & W. Fleischhacker (AT)*

- 09.00** KEYNOTE SPEAKER: Trends in Substance Dependence in Europe: Epidemiology, Policy, Treatment Issues
P. Griffiths (EMCDDA, PT)
- 09.45** Multi-site EU – Cocaine Study
C. Haasen (DE)
- 10.10** Cocaine Vaccination – A New Strategy
T. Kosten (US)

Session 2 – Forgery-proof Drug Testing

- 10.35** Urine Labelling with Orally Applied Marker Substances in Drug Substitution Therapy
R. Keller (DE)

- 11.30** Comfort Break

Session 3 – Delegates can choose either session (a) or (b)

(3a) Alcohol Dependence: Epidemiology & Policy
Chairs: *K. Thau (AT) & M. Dressel (AT)*

- 11.30** Alcohol Trends in Europe
E. Österberg (FI)
- 11.55** Evidence Based Alcohol Policy
B. Baumberg (UK)
- 12.20** Evidence Based Alcohol Policy – an Oxymoron?
A. Uhl (AT)
- 12.45** Evolution of Alcohol Policy in Poland: Between Political and Economic Interests
J. Moskalewicz (PL)

(3b) Opioid Dependence in Eastern European Countries: Hope for changes?

Chairs: *M. Gossop (UK) & A. Uchtenhagen (CH)*

- 11.30** Treatment of Opioid dependence in Russia
V. Mendeleovich (RUS)
- 11.50** Polish Experience of Methadone: Difficulties of scale
M. Beniowski (POL)
- 12.10** Therapeutic Alliance and Drug Treatment: Harm Reduction and Psychosocial Interventions
A. Tatarsky (US)
- 12.30** Methadone and Buprenorphine in the Former Soviet Union: Lessons from the Past Decade
K. Malinowska Sempruch (POL)
- 12.50** Addiction Treatment in Policy Context: Treatment Availability, Accessibility and International Law
D. Wolfe (US)

13.10-14.00 Lunch at the Palais Ferstel

Session 4 – Smoking Addiction and the Management of Smoking Cessation

Chairs: *G. Fischer (AT) & M. Krausz (CA)*

- 14.00** Epidemiology of Nicotine Dependence
A. Rieder (AT)
- 14.25** Neurobiological Bases/Neuroimaging Results in Tobacco Addiction
I. Berlin (FR)
- 14.50** New Pharmacological Developments in Treatment of Nicotine Dependence – Varenicline and More
F. Vocci (NIDA, US)
- 15.15** Relapse and Relapse Prevention
P. Hajek (UK)

- 15.40** Coffee

Session 5 – Health Professionals & Addiction: Time for Strategies

Chairs: *J. Tomas (UNODC) & T. Szekeres (AT)*

- 16.00** Alcohol Use and Illicit Drug Exposure Among Swedish Medical Students and First-Year Interns
M. Dahlin (SE)
- 16.25** Psychological Distress and Drug Consumption among Catalan Doctors: Two Epidemiological Studies
A. Arteman (ES)
- 16.50** The Role of Stress and Burnout in Addicted Health Professionals
R. Tyssen (NO)
- 17.15** Clinical Management of Physicians with Addictive Behaviour
M. Casas (ES)

- 19.15** Welcome Reception – City Hall

Day 2 – Tuesday 11th September 2007

**Session 6 – Opioid Addiction & Pain:
Common Features, Receptors & Treatment**

Chairs: *T. Kosten (US) & S. Rudas (AT)*

- 08.30** KEYNOTE SPEAKER: The Opioid Receptor System: Pain and Addiction
J-K. Zubieta (US)
- 09.15** Overview on Maintenance Therapy in the EU – Treatment Coverage and Efficacy
M. Gossop (UK)
- 09.40** Management of Opioid Maintenance Therapy in Austria: Recent Empirical Study
A. Springer (AT)
- 10.05** RIOTT: UK Trial of European-Style Supervised Injectable Opiate Maintenance – Bureaucratic and Clinical Challenges and Initial Experiences
J. Strang (UK)
- 10.30** Heroin Assisted Treatment: Latest Findings and The International Situation
W. van den Brink (NL)

10.55 Coffee

Session 7 – Delegates can choose either session (a) or (b)

(7a) Compulsory Treatment & Co-morbidity in Substance Dependence

Chairs: *A. Erfurth (AT) & J. Gölz (DE)*

- 11.30** Treatment Alternatives to Imprisonment – What have we Learnt? Results from a European Study on Quasi-Compulsory Treatment
A. Uchtenhagen (CH)
- 11.55** Hepatitis C: Treatment in Opioid Dependent Patients
M. Backmund (DE)
- 12.20** Schizophrenia & Substance Abuse and Dependence
B. Winklbaur (AT)
- 12.45** Bipolar Disorder & Substance Abuse and Dependence
I. Maremmani (EUROPAD, IT)

(7b) New Research Results in Substance Dependence

Chairs: *S. Haas (AT) & C. Haring (AT)*

- 11.30** Alcohol Use and Drug Consumption in Austrian University Students
S. Giacomuzzi (AT)
- 11.45** Slow-release Morphine (SROM)/Methadone Comparison in Slovenia
A. Kastelic (SL)
- 12.00** Predicting treatment response with neuroimaging fMRI, MRSpectroscopy and smoking cessation
C. Schütz (DE)

- 12.15** Sleep quality improvement with melatonin supplement, among methadone maintenance treatment (MMT) patients abusing benzodiazepines (BDZ) – a double blind clinical trial
S. Schreiber (IS)

- 12.30** Strategies of Addiction Policies in Australia
A. Ritter (AUS)

13.10-14.00 Lunch at the Palais Ferstel

Session 8 – Opioid Dependence: New Medication Development

Chairs: *G. Fischer (AT) & M. Potenza (US)*

- 14.00** Australian Trials of Buprenorphine-Naloxone
J. Bell (AUS)
- 14.25** A Stepped Care Approach Using Buprenorphine-Naloxone: Results of an RCT and New Experiences from Sweden
J. Kakko (SE)
- 14.50** Switching Patients from Buprenorphine to Buprenorphine-Naloxone: The Icelandic Experience
V. Rúnarsdóttir (IS)
- 15.15** Buprenorphine-Naloxone as part of General Medical Practice: A U.S. Experience
E. Gunderson (US)
- 15.40** A Randomized, Controlled Comparison of Buprenorphine-Naloxone and Methadone for Opioid Dependence Treatment
J. Kamien (US)

16.05 Coffee

Session 9 – Delegates can choose either session (a) or (b)

(9a) Opioid Dependence: Special Target Groups & Experiences under the Consideration of Opioid Maintenance

Chairs: *A. Ritter (AUS) & K. Mann (DE)*

- 16.30** Trauma & Substance Dependence
M. Krausz (CA)
- 16.55** Substance Dependency and Pregnancy
L. Finnegan (US)
- 17.20** Challenges in Clinical Trial Treatment Implementation with Opioid-Dependant Pregnant Women: The MOTHER Study
A. Arria (US)
- 17.45** Neonatal Abstinence Syndrome in Neonates of Opioid Maintained Women
N. Ebner (AT)

DRAFT PROGRAMME

European Association of Addiction Therapy Conference 2007

Day 2 – Tuesday 11th September 2007 Cont

(9b) Special Research in Addiction: From Non-substance Related Addiction to Substance Dependence

Chairs: *G. Bühringer (DE) & A. Uhl (AT)*

- 16.30** Sensation Seeking and Alexithymia in Different Types of Game: Comparison between Pathological, Regular and Occasional Gamblers
C. Bonnaire (FR)
- 16.55** Conducting a Randomised Controlled Trial with Drug Using Prisoners in the UK: the LEEDS Trial
L. Sheard (UK)
- 17.20** Electronic Buccal Drug delivery System to Treat Addiction and Chronic Diseases
H. Mell (IS)
- 17.45** Pregnancy in Women with Opioid Maintenance: Reactions of the Obstetric Staff
M. Langer (AT), I. Frech (AT)
- 18.30** Poster Tour & Cocktails

18.30-19.30 – in German

Short Symposium for Austrian Physicians

- 20.30** Speakers' Dinner

Day 3 – Wednesday 12th September 2007

Session 10 – Non-Substance Related Addiction Gambling & Eating Disorders: Common Features?

Chairs: *G. Fischer (AT) & F. Vocci (US)*

- 08.30** KEYNOTE SPEAKER: Should Addictive Disorder Include Non-Substance Related Disorders?
M. Potenza (US)
- 09.15** Epidemiology in Pathological Gambling
G. Bühringer (DE)
- 09.40** Neuroimaging Findings in Pathological Gambling
C. Büchel (DE)
- 10.05** Eating Addiction
J. Frascella (NIDA/US)
- 10.30** Serotonergic and Dopaminergic Neurocircuits in Eating Disorders
U. Bailer (AT)

- 10.55** Coffee

Session 11 – ADHD & Substance Use Disorder: An Overlapping Phenomenon

Chairs: *W. van den Brink (NL) & M. Casas (ES)*

- 11.30** Adolescents with ADHD and Substance Use Disorder
K. A. Mirza (UK)
- 11.55** Multi-Professional Treatment of ADHD in Adolescents
Y. Kaminer (US)
- 12.20** Treatment of ADHD in Substance Use Disorders: the European Perspective
P-J. Carpentier (NL)
- 12.45** ADHD and Substance Use Disorders: Findings of a Spanish Adult ADHD Sample
J. Antoni Ramos-Quiroga (ES)

- 13.10-14.00** Lunch at the Palais Ferstel

Session 12 – Alcohol Dependence: Neurobiological Aspects & New Treatment Options

Chairs: *K. Mann (DE) & F. Wurst (AT)*

- 14.00** Neurobiological Basis of Alcohol Addiction – Gender Differences
K. Mann (DE)
- 14.25** State of the Art in the Treatment of Alcohol Dependence
O. Lesch (AT)
- 14.50** New Biomarkers of Alcohol Consumption: Diagnostic and Therapeutic Aspects
F. Wurst (AT)
- 15.15** Memantine and Escitalopram in the Treatment of Alcohol Dependence in Patients with Co-Morbid Major Depression – a Randomized, Double-Blind Study
H. Alho (ISAM, FI)

POSTER AWARD – THREE AWARDEES

- 15.40** Closing Address
- 16.05** End of Conference

The conference organisers reserve the right to amend the programme without notice

Tel: +44 (0)20 8487 1421

Email: info@eat.org

Programme and registration available online at www.eat.org

Supported by educational grants from:

